Allovectin- 7 is designed to deliver to tumor cells a gene encoding a foreign tissue antigen, which is expected to trigger an immune system attack against the cancerous cells

Allovectin- 7 is designed to deliver to tumor cells a gene encoding a foreign tissue antigen, which is expected to trigger an immune system attack against the cancerous cells

Cytogen said it also has an agreement with Fletcher to sell up to 675,000 addition shares to the investment firm between Oct. 13, 1995 and March 29, 1996. * Oxigene Inc., of New York, said a Phase I study of Neu-Sensamide, a high dose form of metoclopramide to enhance radiation and chemotherapy treatments and reduce vomiting, showed Neu-Sensamide injections achieved 95 percent bioavailability when compared with intravenous infusions of metoclopramide...Oxigene expects to begin Phase III studies

The two companies said the goal is to make a "business card-size device" to conduct the drug discovery...The Sarnoff center created a new company, Orchid Biocomputer Inc., of Princeton, to conduct the research with SmithKline. * The Canadian government funded Bacterial Diseases Network and Genetics Disease Network, both of Edmonton, entered into a three-year agreement with Sciex, of Ontario, and the University of Alberta to develop rapid gene sequencing technology

Ampalex, a compound designed to improve the function of the ampa receptor, is being developed for treatment of memory and cognition deficits in patients with Alzheimer's disease...The company said the move was not in response to any specific acquisition attempt. * Neurogen Corp., of Branford, Conn., boosted the amount of its August public offering to $46 million with the sale of another 375,000 shares to the underwriters _ Smith Barney Inc., of New York, and Robertson Stephens & Co

to acquire its subsidiary, Rh Pharmaceuticals Inc., of Winnipeg, Manitoba...One is for a project to develop new drugs for inflammatory bowel disease...the other for development of discovery technology based on the use of the micro-organism Dictyostelium (slime mold). (c) 1997 American Health Consultants

Ostex wants to confirm termination of its license and distribution, and research and development agreements with Boehringer because, it alleged, Boehringer failed to meet marketing obligations for Osteomark kits in the microtiter plate format...Cytogen Corp., of Princeton, N.J., signed letters of intent with CIS bio international (CIS), of France, to market OncoScint CR/OV, an imaging agent to detect ovarian and colorectal cancers, in Europe and other areas outside North America

Both trials, expected to be complete by the third quarter of 1996, are equivalence studies testing Magainin's product against the standard antibiotic treatment, ofloxacin. * Matrix Pharmaceutical Inc., of Menlo Park, Calif., submitted a marketing authorization application for its Accusite injectable gel to the European Union's Committee for Proprietary Medicinal Products (CPMP...In August, Upjohn and Sweden-based Pharmacia AB agreed to merge creating a company valued at $13 billion. (c) 1997

The company said the studies demonstrate the diagnostic, which is an antibody fragment labeled with technetium-99m, can be used to detect the spread of colorectal cancer...CEA-Scan has been submitted for approval in the U.S., Canada and Europe as a diagnostic for the disease. * Perkin-Elmer Corp., of Norwalk, and the National Center for Genome Resources, which houses a U.S.- government sponsored DNA sequence data base in Santa Fe, N.M., have entered into a collaboration to develop software for

It is designed to attach to the beta-glucan receptor on the surface of white blood cells to boost their response to pathogens. * Immunomedics Inc., of Morris Plains, N.J., said pilot clinical trials of its humanized mouse monoclonal antibody for cancers with the carcinoembryonic antigen (CEA) demonstrated the drug had low immunogenicity and high specific binding to the disease targets

Connective Therapeutics Inc., of Palo Alto, Calif., said Phase I studies of recombinant human relaxin for scleroderma showed the agent to be safe...PRO 2000 is designed to block the binding of gp120, a glycoprotein found on the surface of HIV, to the CD4 protein. (c) 1997 American Health Consultants

LMIs are combinations of isolated tumor antigens and cell-size microspheres, which are injected in cancer patients and are designed to stimulate tumor- specific cytotoxic T lymphocytes. * Ligand Pharmaceuticals Inc., of San Diego, and Allergan Ligand Retinoid Therapeutics Inc. (ALRT) settled their patent battle with La Jolla Cancer Research Foundation, of La Jolla, Calif., and SRI International, of Menlo Park, Calif...patents on retinoid technology licensed to Ligand and ALRT by the Salk Institute

The most advanced form, Vistide, is administered intravenously and Gilead expects to file a new drug application for the product with the FDA by the end of 1995. * ID Biomedical Corp., of Vancouver, British Columbia, said stock options exercised by employees and members of the board of directors for 548,000 common shares yielded $5.5 million Canadian (about $4 million U.S.) to the company. * ImmunoGen Inc., of Cambridge, Mass., raised $3.6 million through the sale of subordinated convertible

The company said the placement is part of an agreement to sell up to 9.7 million restricted shares and warrants for another 5 million shares during the third quarter. * LeuKoSite Inc., of Cambridge, Mass., expanded its 1994 collaboration with Warner-Lambert Co., of Morris Plains, N.J., to develop small molecule inhibitors of chemokines, which are believed to be involved in inflammatory and autoimmune diseases

29, 1995 to determine whether fenfluramine and its isomers should be removed from the federal list of controlled substances. * PerSeptive Biosystems Inc., of Farmingham, Mass., said the U.S. District Court in Boston accepted settlement of a class action shareholder lawsuit against the company...The suit was filed in 1994 after PerSeptive was forced to recalculate a series of quarterly financial statements...The takeover was announced in July. (See BioWorld Today Special News Bulletin, July 10, 1995

A designation as a combination product, based on the product's glycerol content, would have required Osteotech to conduct clinical studies. * Protein Polymer Technologies Inc., of San Diego, said holders of its Series C preferred stock provided the company with a $500,000 bridge loan. (c) 1997 American Health Consultants

GeneMedicine Inc., of The Woodlands, Texas, and Medi-Ject Corp., of Minneapolis, are collaborating to develop needle-free injection devices to enhance the delivery of genes to certain tissues. * HemaSure Inc., of Marlborough, Mass., registered to sell 2.5 million shares of common stock. * Mycogen Corp., of San Diego, and Ciba-Geigy Ltd.'s Seed Division, of Greensboro, N.C., received Environmental Protection Agency approval to market seeds for corn hybrids that are genetically engineered to

The drug uses a CD4 protein to attract the virus and remove it from the bloodstream

The company's lead compound, Synovir, whose generic name is thalidomide, is for HIV, cachexia associated with AIDS, cancer and rheumatoid arthritis. * CellPro Inc., of Seattle, said a federal district court jury in Delaware has decided that the company's Ceprate SC Stem Cell Concentration System and its Ceprate LC Laboratory Cell Separation System do not infringe patents held by Johns Hopkins University, of Baltimore, and licensed to Becton Dickinson and Co., of Franklin Lakes, N.J., and Baxter